HLAG antibody (PE)

Catalog No. ABIN94373

Product Details anti-HLAG Antibody (PE)

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This HLAG antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Specificity: The antibody MEM-G/9 reacts with an extracellular epitope on native form of human HLA-G1 on the cell surface as well as with soluble HLA-G5 isoform in its beta2-microglobulin associated form. Reactivity with HLA-G3 was also reported. The antibody MEM-G/9 is standard reagent thoroughly validated during 3rd International Conference on HLA-G (Paris, 2003).

No Cross-Reactivity: Mouse

Cross-Reactivity (Details): Human

Purification: Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Immunogen: Recombinant human HLA-G refolded with beta2-microglobulin and peptide.

Clone: MEM-G-9

Isotype: IgG1

Application Details

Application Notes: Flow cytometry: Recommended dilution: 1-4 μg/mL, positive control: JEG-3 human choriocarcinoma cell line.

Comment:

The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.

Restrictions: For Research Use only

Handling

Concentration: 0.1 mg/mL

Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.
Avoid prolonged exposure to light.

Storage: 4 °C

Storage Comment: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

References for anti-HLAG antibody (PE) (ABIN94373)

Horii, Bui, Touma, Cho, Parast: "An Improved Two-Step Protocol for Trophoblast Differentiation of Human Pluripotent Stem Cells." in: Current protocols in stem cell biology, Vol. 50, Issue 1, pp. e96, (2020) (PubMed).

Spurny, Kailayangiri, Altvater, Jamitzky, Hartmann, Wardelmann, Ranft, Dirksen, Amler, Hardes, Fluegge, Meltzer, Farwick, Greune, Rossig: "T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G." in: Oncotarget, Vol. 9, Issue 5, pp. 6536-6549, (2018) (PubMed).

Otti, Saleh, Velicky, Fiala, Pollheimer, Knöfler: "Notch2 controls prolactin and insulin-like growth factor binding protein-1 expression in decidualizing human stromal cells of early pregnancy." in: PLoS ONE, Vol. 9, Issue 11, pp. e112723, (2014) (PubMed).

Zhao, Teklemariam, Hantash: "Reassessment of HLA-G isoform specificity of MEM-G/9 and 4H84 monoclonal antibodies." in: Tissue antigens, Vol. 80, Issue 3, pp. 231-8, (2012) (PubMed).

López, Alegre, LeMaoult, Carosella, González: "Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells." in: Molecular immunology, Vol. 43, Issue 14, pp. 2151-60, (2006) (PubMed).

Gonen-Gross, Achdout, Arnon, Gazit, Stern, Horejsí, Goldman-Wohl, Yagel, Mandelboim: "The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 175, Issue 8, pp. 4866-74, (2005) (PubMed).

Menier, Saez, Horejsi, Martinozzi, Krawice-Radanne, Bruel, Le Danff, Reboul, Hilgert, Rabreau, Larrad, Pla, Carosella, Rouas-Freiss: "Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules." in: Human immunology, Vol. 64, Issue 3, pp. 315-26, (2003) (PubMed).

Lozano, González, Kindelán, Rouas-Freiss, Caballos, Dausset, Carosella, Peña: "Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule." in: AIDS, Vol. 16, Issue 3, pp. 347-51, (2002) (PubMed).

Pangault, Le Friec, Caulet-Maugendre, Léna, Amiot, Guilloux, Onno, Fauchet: "Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases." in: Human immunology, Vol. 63, Issue 2, pp. 83-90, (2002) (PubMed).

Fuzzi, Rizzo, Criscuoli, Noci, Melchiorri, Scarselli, Bencini, Menicucci, Baricordi: "HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy." in: European journal of immunology, Vol. 32, Issue 2, pp. 311-5, (2002) (PubMed).

Fournel, Huc, Aguerre-Girr, Solier, Legros, Praud-Brethenou, Moussa, Chaouat, Berrebi, Bensussan, Lenfant, Le Bouteiller: "Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules." in: Tissue antigens, Vol. 55, Issue 6, pp. 510-8, (2000) (PubMed).

Target Details for HLAG

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Alternative Name: HLA-G (HLAG Products)

Synonyms: MHC-G antibody, B-F antibody, B-F-S04 antibody, B-F-S05 antibody, B-F-S06 antibody, B-F-S07 antibody, B-FI antibody, B-FIV antibody, BF2 antibody, BFa2 antibody, BFw-03 antibody, BFw-05 antibody, BFz-01 antibody, major histocompatibility complex, class I, G antibody, MHC BF1 class I antibody, HLA-G antibody, BF1 antibody

Background: Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.

Gene ID: 3135

UniProt: P17693

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response